The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...

AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.

Benefiting from the news, however, was Bristol Myers Squibb Co., which gained U.S. FDA approval in September 2024 for Cobenfy (xanomeline-trospium), a dual M1/M4 muscarinic agonist, with shares ...

During the quarter, Bristol-Myers achieved a major milestone by securing Food and Drug Administration (FDA) approval for Cobenfy. With Cobenfy, Bristol-Myers is not just expanding its portfolio ...

However, this came as good news for investors in AbbVie’s peer Bristol Myers Squibb (NYSE:BMY) as the company recently secured the U.S. FDA approval for its schizophrenia drug Cobenfy ...

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

Bristol-Myers Squibb has also been making strides in clinical trials. Notably, the FDA approved Cobenfy, a new treatment for schizophrenia, and the company reported promising news about milvexian.

Emraclidine's failure in phase 2 trials is a significant setback for AbbVie's neuroscience pipeline. This was a very surprising outcome after very strong phase 1b results and the success of ...